Lung Cancer Research Foundation Awards $1.5 Million for New Treatments for EGFR-Mutant Patients

Lung Cancer Research Foundation Grants Team Science Award

The Lung Cancer Research Foundation (LCRF) has recently made headlines by awarding its first Team Science Award to two research teams focused on advancing therapies for EGFR-mutant lung cancer. This award comes with a generous funding of $1.5 million, made possible through a donation from Benay and Steven Taub. This funding aims to innovate treatment strategies for patients suffering from this aggressive form of lung cancer.

Key Researchers Involved

Leading the research efforts are prominent figures in oncology, Dr. Kwok-Kin Wong and Dr. Matthew Meyerson. Dr. Wong serves as the Principal Investigator and is a professor at the NYU Grossman School of Medicine. He will oversee the project’s first phase, focusing on novel therapeutic strategies. Meanwhile, Dr. Meyerson, who leads the second phase, is a professor at Harvard Medical School and the Dana-Farber Cancer Institute. Both are renowned for their pioneering work in the realm of EGFR-mutant lung cancer.

Understanding EGFR-Mutant Lung Cancer

Lung cancer remains the leading cause of cancer-related fatalities worldwide. Within this category, lung adenocarcinoma (LUAD), which accounts for around 10% of lung cancers among individuals of European and African descent and up to 45% among those of East Asian ancestry, is frequently associated with mutations in the epidermal growth factor receptor (EGFR) gene. Existing treatments, such as tyrosine kinase inhibitors (TKIs) like osimertinib, have yielded improvements in patient outcomes; however, the challenge of drug resistance is significant. Many patients experience a relapse, with median survival rates remaining around 39 months.

Resistance mechanisms can emerge in various ways, including additional mutations within the EGFR gene, activation of alternative signaling pathways, or even cellular transformations. Disturbingly, in almost half of relapsed patients, the specific causes of resistance remain elusive, presenting ongoing hurdles in treatment strategies for EGFR-mutant cancer.

Innovative Research Approaches

The teams led by Dr. Wong and Dr. Meyerson are embarking on an ambitious project that seeks to unravel these resistance mechanisms. They have discovered a gene whose deactivation appears to increase the sensitivity of cancer cells to osimertinib, potentially preventing the onset of drug resistance. This research is divided into two separate yet complementary projects.

Project 1 will explore various drug combinations using mouse models that closely resemble human lung cancer to analyze how these combinations affect cancer biology and progression.

Project 2 will test the drug combinations on human patients, targeting a specific phase II clinical trial set to commence with high-risk EGFR-mutant non-small cell lung cancer (NSCLC) patients. This phase aims to determine whether a preemptive combination therapy could significantly reduce the chance of developing resistant cancer cells.

Dr. Wong encapsulates the project's objective with, “We aim to prevent resistance before it begins.” This approach involves initiating treatment with a combination of therapies designed to eradicate a larger proportion of cancer cells early in the treatment process, thereby lowering the likelihood that resistant variants will emerge.

Dr. Meyerson further emphasizes the potential patient benefits, stating, “If we can identify a combination therapy that heads off resistance, then we are one step closer to curing this type of lung cancer.” Such advancements could significantly enhance the quality of life for patients whose tumors harbor EGFR mutations.

Future Implications

This innovative research is already catching the attention of the medical community, with Dr. Antoinette Wozniak, Chief Scientific Officer for LCRF, highlighting the project’s promising prospects in revolutionizing how EGFR-mutant lung cancer is treated. By providing early intervention options before resistance occurs, the researchers' work could lead to lasting improvements in survival rates.

LCRF has a history of funding valuable research, having supported early-career work that laid the groundwork for the advancements seen in targeted lung cancer treatments today. The Team Science Award serves as a continuation of this legacy, as both Dr. Wong and Dr. Meyerson aim to eradicate EGFR-mutant lung cancer.

For further information about this grant and ongoing projects, visit LCRF.org/CurrentResearch.

About LCRF: The Lung Cancer Research Foundation works tirelessly to boost research aimed at improving lung cancer outcomes and enhancing quality of life. To date, they have funded 450 research grants, totaling nearly $53 million, marking their commitment to this cause.